Maintenance chemo may slow mesothelioma, but not extend life
NCT ID NCT07411144
First seen Feb 18, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tested whether continuing gemcitabine chemotherapy after initial treatment can delay cancer progression in patients with diffuse pleural mesothelioma, a rare and aggressive lung lining cancer. 64 patients who responded to first-line chemotherapy were randomly assigned to receive gemcitabine or no further treatment. Results suggest gemcitabine may slow cancer growth but does not clearly extend overall survival, and side effects are common.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE PLEURAL MESOTHELIOMA (DPM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Institute, Cairo University
Cairo, Egypt, 11765, Egypt
Conditions
Explore the condition pages connected to this study.